Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase NA 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Colorectal Neoplasms 29Prostatic Neoplasms 28Neoplasms 28Breast Neoplasms 27Neoplasm Metastasis 26Multiple Myeloma 24Pancreatic Neoplasms 22Recurrence 18Ovarian Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Melanoma 17Lymphoma, Non-Hodgkin 17Triple Negative Breast Neoplasms 16Lymphoma, Large B-Cell, Diffuse 15Leukemia, Myeloid, Acute 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Burkitt Lymphoma 14Lung Neoplasms 13Carcinoma, Renal Cell 13Stomach Neoplasms 12Lymphoma, Follicular 12Lymphoma 12Endometrial Neoplasms 12Advanced Solid Tumors 12Small Cell Lung Carcinoma 11Glioblastoma 11Colonic Neoplasms 11Leukemia, Lymphocytic, Chronic, B-Cell 10Uterine Cervical Neoplasms 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Cancer × 30 days × Clear all
NCT07605962 2026-05-26

Phase 1/2 Study of UI-102 in Selected Advanced Cancers

United Immunity, co., Ltd.

Phase 1/2 Not yet recruiting
140 enrolled

Advanced Cancer

NCT06656390 2026-05-22

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

Shanghai Allink Biotherapeutics Co., Ltd.

Phase 1/2 Recruiting
202 enrolled
Other solid neoplasm

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡